{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:53:36Z","timestamp":1792511616234,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients with plasma cell leukemia (PCL) are generally excluded from pivotal T-cell\u2013redirecting bispecific antibody (BsAb) trials. We evaluated real-world outcomes in a multicenter retrospective study of 122 patients with primary or secondary PCL across 15 academic centers, categorized as active (\u22655% circulating plasma cells within 30 days before BsAb initiation) or historical. Patients received teclistamab (37%), elranatamab (11%), talquetamab as a line of therapy (Tal LOT, 42%), or talquetamab as bridging to CAR T-cell therapy (Tal Bridge, 11%). Cytokine release syndrome was grade 1 to 2 in 56% and grade 3 to 4 in 4% of patients, whereas neurotoxicity was grade 1 to 2 in 16% and grade 3 to 4 in 5% of patients. The overall response rate was 55%, including 61% with Tal LOT, 58% with Tal Bridge, 46% with elranatamab, and 33% with teclistamab. With a median follow-up of 8.3 months, talquetamab demonstrated superior survival. Tal LOT showed a median progression-free survival (mPFS) of 5.5 months and a median overall survival (mOS) of 11.5 months, and both were unreached in the Tal Bridge cohort. In contrast, teclistamab and elranatamab showed a mPFS values of 1.2 and 1.6 months and mOS values of 8.1 and 3.6 months, respectively (P = .007, P = .023). In active PCL, Tal LOT achieved mPFS\/mOS of 6.9\/12.2 months vs 0.7\/1.4 months with teclistamab and 1.0\/3.1 months with elranatamab, respectively (P&amp;lt; .001, P = .002). Multivariable analysis associated active PCL with worse survival and Tal LOT with improved outcomes. BsAbs were well tolerated in PCL, with talquetamab showing superior outcomes compared with B-cell maturation antigen\u2013directed BsAbs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020826","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:54:27Z","timestamp":1783032867000},"page":"5938-5950","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6590","authenticated-orcid":false,"given":"Mahmoud R.","family":"Gaballa","sequence":"first","affiliation":[{"name":"1Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley","family":"Julian","sequence":"additional","affiliation":[{"name":"2Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"4H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[{"name":"5Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-7975","authenticated-orcid":false,"given":"Danai","family":"Dima","sequence":"additional","affiliation":[{"name":"7Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma","family":"Rana","sequence":"additional","affiliation":[{"name":"8Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0475-9666","authenticated-orcid":false,"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[{"name":"9Division of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"8Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3678-2805","authenticated-orcid":false,"given":"Lindsay","family":"Fogel","sequence":"additional","affiliation":[{"name":"10John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"5Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[{"name":"7Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh S.","family":"Zanwar","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-1634","authenticated-orcid":false,"given":"Azra","family":"Borogovac","sequence":"additional","affiliation":[{"name":"11City of Hope Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James","family":"Davis","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Medical Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1150-5506","authenticated-orcid":false,"given":"Kimberly","family":"Green","sequence":"additional","affiliation":[{"name":"12Division of Hematology and Medical Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"10John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3022-2547","authenticated-orcid":false,"given":"Eli","family":"Zolotov","sequence":"additional","affiliation":[{"name":"10John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan","family":"Herr","sequence":"additional","affiliation":[{"name":"13Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[{"name":"14Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Ouchveridze","sequence":"additional","affiliation":[{"name":"14Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"DeJarnette","sequence":"additional","affiliation":[{"name":"14Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"15Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[{"name":"15Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Richards","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1128-0445","authenticated-orcid":false,"given":"Muhammad Bilal","family":"Abid","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Medical Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3778-5499","authenticated-orcid":false,"given":"Hossam M.","family":"Ali","sequence":"additional","affiliation":[{"name":"5Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Christine","family":"Ye","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2510-6536","authenticated-orcid":false,"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth","family":"Shain","sequence":"additional","affiliation":[{"name":"4H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda-Puglianini","sequence":"additional","affiliation":[{"name":"4H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Harada","sequence":"additional","affiliation":[{"name":"4H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[{"name":"4H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-2703","authenticated-orcid":false,"given":"Hamza","family":"Hassan","sequence":"additional","affiliation":[{"name":"13Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"3Myeloma, Waldenstrom\u2019s, and Amyloidosis Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"15Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"5Cleveland Clinic Taussig Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"8Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[{"name":"7Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-8007","authenticated-orcid":false,"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[{"name":"11City of Hope Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-3292","authenticated-orcid":false,"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"18Sarah Cannon Research Institute, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"6Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Grajales-Cruz","sequence":"additional","affiliation":[{"name":"4H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Division of Cancer Medicine, Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[{"name":"2Huntsman Cancer Institute at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"1","key":"2026090811323493000_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-022-05058-5","article-title":"The emerging therapeutic landscape of relapsed\/refractory multiple myeloma","volume":"102","author":"Tanenbaum","year":"2023","journal-title":"Ann Hematol"},{"issue":"18","key":"2026090811323493000_bib2","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple myeloma-a promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"issue":"22","key":"2026090811323493000_bib3","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"2026090811323493000_bib4","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026090811323493000_bib5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2026090811323493000_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2026090811323493000_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026090811323493000_bib8","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/s41375-025-02653-z","article-title":"Peripheral blood flow cytometry-based definition of plasma cell leukemia","volume":"39","author":"Bohra","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"2026090811323493000_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-018-0059-6","article-title":"Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group","volume":"8","author":"Katodritou","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"2026090811323493000_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2021.01.002","article-title":"Efficacy of daratumumab-based regimens for the treatment of plasma cell leukemia","volume":"21","author":"Parrondo","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2026090811323493000_bib11","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"S1","key":"2026090811323493000_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5045\/br.2022.2022033","article-title":"Update on primary plasma cell leukemia","volume":"57","author":"Jung","year":"2022","journal-title":"Blood Res"},{"issue":"4","key":"2026090811323493000_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/leu.2012.336","article-title":"Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group","volume":"27","author":"Fern\u00e1ndez de Larrea","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2026090811323493000_bib14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3390\/cancers16112149","article-title":"A clinical perspective on plasma cell leukemia: a single-center experience","volume":"16","author":"Li","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2026090811323493000_bib15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(23)00405-9","article-title":"Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12\/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study","volume":"24","author":"van de Donk","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026090811323493000_bib16","doi-asserted-by":"crossref","first-page":"1495233","DOI":"10.3389\/fimmu.2024.1495233","article-title":"Anti-BCMA and GPRC5D bispecific antibodies in relapsed\/refractory primary plasma cell leukemia: a case report","volume":"15","author":"Bernardi","year":"2024","journal-title":"Front Immunol"},{"issue":"8","key":"2026090811323493000_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2026090811323493000_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026090811323493000_bib19","author":"National Cancer Institute","year":"2017"},{"issue":"10","key":"2026090811323493000_bib20","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"2026090811323493000_bib21","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1182\/bloodadvances.2025016695","article-title":"The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia","volume":"9","author":"Shrestha","year":"2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026090811323493000_bib22","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026090811323493000_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026090811323493000_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clml.2024.10.014","article-title":"Clinical characteristics and survival outcomes of patients with primary and secondary plasma cell leukemia according to the 2021 definition: a single center retrospective study","volume":"25","author":"Shalaby","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2026090811323493000_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.26891","article-title":"Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: a multicenter study by the Greek myeloma study group","volume":"98","author":"Katodritou","year":"2023","journal-title":"Am J Hematol"},{"issue":"25","key":"2026090811323493000_bib26","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026090811323493000_bib27","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1038\/s41375-025-02757-6","article-title":"Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma","volume":"39","author":"Neubert","year":"2025","journal-title":"Leukemia"},{"issue":"23","key":"2026090811323493000_bib28","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2025016966","article-title":"Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia","volume":"9","author":"Galarza Fortuna","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026090811323493000_bib29","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/bloodadvances.2025018342","article-title":"Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability","volume":"10","author":"Mohan","year":"2026","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5938\/2541830\/blooda_adv-2026-020826-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/17\/5938\/2541830\/blooda_adv-2026-020826-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:39Z","timestamp":1788881559000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/17\/5938\/569502\/Real-world-outcomes-with-BCMA-and-GPRC5D-targeting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,9,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020826","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,8]]},"published":{"date-parts":[[2026,8,28]]}}}